Please Wait
Applying Filters...
menu
    • menu
    Egis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.

    Virtual Booth

    Contact Supplier

    Kewpie is your partner for Sodium Hyaluronate & Hyaluronic Acid// CEP, USDMF, KDMF & JDMF registered.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2025-03-24

    Virtual Booth

    Contact Supplier

    Centrient is a leading manufacturer of Beta-Lactam Antibiotics and a provider of next-generation Statins and Antifungals.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2025-03-17

    Virtual Booth

    Contact Supplier

    Menu

    Tuspetinib

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Aptose Reports Year End 2024 Results and Corporate Highlights
    Aptose Reports Year End 2024 Results and Corporate Highlights

    28 Mar 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/03/28/3051334/35575/en/Aptose-Reports-Year-End-2024-Results-and-Corporate-Highlights.html

    GLOBENEWSWIRE
    28 Mar 2025
    Share Share
    Aptose Gets CSRC Nod To Escalate Dosing In Ph 1/2 Tuscany Trial
    Aptose Gets CSRC Nod To Escalate Dosing In Ph 1/2 Tuscany Trial

    20 Feb 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/02/20/3029546/35575/en/Aptose-Announces-Positive-Clinical-Safety-Review-Committee-CSRC-Approval-to-Dose-Escalate-in-Phase-1-2-Tuscany-Trial-of-Frontline-Triple-Drug-Therapy-with-Tuspetinib-Amid-Complete-.html

    GLOBENEWSWIRE
    20 Feb 2025
    Share Share
    Aptoses’ Tuspetinib Shows Responses In AML Ph 1/2 TUSCANY Trial
    Aptoses’ Tuspetinib Shows Responses In AML Ph 1/2 TUSCANY Trial

    12 Feb 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/02/12/3024897/35575/en/Aptose-s-Frontline-Triple-Drug-Therapy-with-Tuspetinib-Achieves-Notable-Responses-in-Newly-Diagnosed-AML-Patients-in-the-Phase-1-2-TUSCANY-Trial.html

    GLOBENEWSWIRE
    12 Feb 2025
    Share Share
    Aptose Begins Dosing AML Patients With Tuspetinib Triplet In Trial
    Aptose Begins Dosing AML Patients With Tuspetinib Triplet In Trial

    09 Jan 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/01/09/3007341/35575/en/Aptose-Announces-First-AML-Patients-Dosed-with-Tuspetinib-Triplet-Frontline-Therapy-in-TUSCANY-Trial.html

    GLOBENEWSWIRE
    09 Jan 2025
    Share Share
    Aptose Publishes Preclinical on Tuspetinib’s Action in AML Cells
    Aptose Publishes Preclinical on Tuspetinib’s Action in AML Cells

    12 Dec 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/12/12/2996333/35575/en/Aptose-Announces-Publication-of-Preclinical-Data-in-AACR-Journal-Demonstrating-Tuspetinib-s-Unique-Mechanism-of-Action-and-Synthetic-Lethality-on-AML-Cells-When-Combined-with-Venet.html

    GLOBENEWSWIRE
    12 Dec 2024
    Share Share
    Aptose Data Supports Tuspetinib Triple Drug Therapy for AML
    Aptose Data Supports Tuspetinib Triple Drug Therapy for AML

    09 Dec 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/12/09/2993973/35575/en/Aptose-Clinical-Data-Featured-in-Poster-Presentation-at-the-2024-ASH-Annual-Meeting-Support-Tuspetinib-Triple-Drug-Therapy-for-Newly-Diagnosed-AML.html

    GLOBENEWSWIRE
    09 Dec 2024
    Share Share